Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
SPECTROBID (bacampicillin hydrochloride) is an oral beta-lactam antibiotic belonging to the aminopenicillin class, used to treat bacterial infections caused by susceptible organisms. It is a prodrug that is hydrolyzed to ampicillin in vivo, providing broad-spectrum coverage against gram-positive and gram-negative bacteria. The drug works by inhibiting bacterial cell wall synthesis through penicillin-binding protein interaction.
As a legacy oral antibiotic approaching loss of exclusivity, SPECTROBID operates in a mature, commoditized market with declining promotional investment and minimal commercial team expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SPECTROBID offers limited career growth potential given its LOE-approaching lifecycle and minimal linked job openings. This role is best suited for professionals seeking stable, maintenance-oriented positions in a mature product franchise rather than high-visibility launch or growth assignments.
Worked on SPECTROBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.